PK
TTRX

Pflug Koory’s Turn Therapeutics TTRX Stock Holding History

Pflug Koory’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$544 Hold
170
– – ﹤0.01% 410
2025
Q4 		$670 Buy
+170
New +$709 ﹤0.01% 407

Other funds holding TTRX

DI
DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pflug Koory's TTRX Position: Q1 2026 in Review

Pflug Koory held its Turn Therapeutics (TTRX) position steady in Q1 2026 at 170 shares worth $544. The position accounts for ﹤0.01% of the portfolio, ranked #410.

Pflug Koory first reported a position in TTRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $670 in Q4 2025. 20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

  • Pflug Koory held 170 shares of Turn Therapeutics worth $544 as of Q1 2026.
  • Pflug Koory left its Turn Therapeutics share count unchanged in Q1 2026.
  • Turn Therapeutics made up ﹤0.01% of Pflug Koory's portfolio in Q1 2026, its #410 holding.
  • Pflug Koory first reported a position in Turn Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pflug Koory's Turn Therapeutics position peaked at $670 in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on Pflug Koory's 13F filing for Q1 2026, filed 22 Apr 2026.